Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 13M | 14M | 21M | 29M | 24M |
| Gross Profit | 5M | 5M | 6M | 8M | 9M |
| Operating Income | -3M | -4M | -5M | 697K | 3M |
| EBITDA | -4M | -9M | -4M | -1M | 3M |
| Net Income | -7M | -11M | -9M | -4M | 729K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.282
-42.45% today
1Y Change
+1430.00%
Window
Jun 23, 2025 → May 26, 2026
Coverage: 233 bars · Jun 23, 2025 → May 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vibe Growth Corporation (VIBEF) is a Healthcare stock with listed on OTC. The stock last traded around $0.28 and up 1430.0% across the available one-year price window (Jun 23, 2025 → May 26, 2026). Baseline metrics include revenue growth of +37.9%, EPS growth of +62.3%, a dividend yield of 0.0%. What stands out right now is revenue +37.9%, EPS +62.3%, free cash flow -91.5% with operating margin 3.3% and ROIC -11.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VIBEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VIBEF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VIBEF Max Drawdown
-78.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VIBEF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$24.2M
-17.2% YoY
FY Net Income
$728.6K
+116.9% YoY
Free Cash Flow
$193.4K
+102.7% YoY
Revenue Growth
+37.9%
EPS Growth
+62.3%
Gross Margin
43.2%
Net Margin
-14.1%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 13M | 14M | 21M | 29M | 24M |
| Gross Profit | 5M | 5M | 6M | 8M | 9M |
| Operating Income | -3M | -4M | -5M | 697K | 3M |
| EBITDA | -4M | -9M | -4M | -1M | 3M |
| Net Income | -7M | -11M | -9M | -4M | 729K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 1M | 5M | 9M | 2M |
| Total Assets | 11M | 16M | 26M | 33M | 18M |
| Total Liabilities | 17M | 15M | 14M | 12M | 8M |
| Shareholder Equity | -5M | 1M | 12M | 21M | 10M |
| Total Debt | 3M | 3M | 3M | 3M | 3M |
| Net Debt | 2M | 2M | -1M | -6M | 156K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
724K
-14.7% YoY
Capital Expenditures
531K
+93.4% YoY
Free Cash Flow
193K
+102.7% YoY
Key ratios
Gross Margin
43.2%
Operating Margin
3.3%
Net Margin
-14.1%
ROE
39.0%
Debt / Equity
-0.32x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.